NCT01558219View on ClinicalTrials.gov

Second-line Chemotherapy in Castration Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

cabacitaxel

Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week

Trial Locations (1)

33520

Tampere University Hospital, Tampere

All Listed Sponsors
collaborator

Helsinki University Central Hospital

OTHER

collaborator

Turku University Hospital

OTHER_GOV

collaborator

Kuopio University Hospital

OTHER

collaborator

Seinajoki Central Hospital

OTHER

lead

Tampere University Hospital

OTHER

NCT01558219 - Second-line Chemotherapy in Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter